| Company/Division name | Fujifilm Diosynth Biotechnologies |
| Parent company | Fujifilm Corporation |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 40 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Boston |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | viral vectors, viral vaccines |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Proximity to customers/market |
